Eliana Merrill's questions to Arrowhead Pharmaceuticals Inc (ARWR) leadership • Q3 2025
Question
Eliana Merrill's representative asked for the company's latest estimates on the size of the addressable patient population for homozygous familial hypercholesterolemia (HoFH).
Answer
SVP Andy Davis stated that the literature suggests a prevalence for HoFH between one in 500,000 to one in a million people, and Arrowhead views the accessible patient population as being consistent with those estimates.